HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Discontinuing noninvasive ventilation in severe chronic obstructive pulmonary disease exacerbations: a randomised controlled trial.

Abstract
We assessed whether prolongation of nocturnal noninvasive ventilation (NIV) after recovery from acute hypercapnic respiratory failure (AHRF) in chronic obstructive pulmonary disease (COPD) patients with NIV could prevent subsequent relapse of AHRF.A randomised controlled trial was performed in 120 COPD patients without previous domiciliary ventilation, admitted for AHRF and treated with NIV. When the episode was resolved and patients tolerated unassisted breathing for 4 h, they were randomly allocated to receive three additional nights of NIV (n=61) or direct NIV discontinuation (n=59). The primary outcome was relapse of AHRF within 8 days after NIV discontinuation.Except for a shorter median (interquartile range) intermediate respiratory care unit (IRCU) stay in the direct discontinuation group (4 (2-6) versus 5 (4-7) days, p=0.036), no differences were observed in relapse of AHRF after NIV discontinuation (10 (17%) versus 8 (13%) for the direct discontinuation and nocturnal NIV groups, respectively, p=0.56), long-term ventilator dependence, hospital stay, and 6-month hospital readmission or survival.Prolongation of nocturnal NIV after recovery from an AHRF episode does not prevent subsequent relapse of AHRF in COPD patients without previous domiciliary ventilation, and results in longer IRCU stay. Consequently, NIV can be directly discontinued when the episode is resolved and patients tolerate unassisted breathing.
AuthorsJacobo Sellares, Miquel Ferrer, Antonio Anton, Hugo Loureiro, Carolina Bencosme, Rodrigo Alonso, Pilar Martinez-Olondris, Javier Sayas, Patricia Peñacoba, Antoni Torres
JournalThe European respiratory journal (Eur Respir J) Vol. 50 Issue 1 (07 2017) ISSN: 1399-3003 [Electronic] England
PMID28679605 (Publication Type: Clinical Trial, Phase IV, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
CopyrightCopyright ©ERS 2017.
Topics
  • Aged
  • Disease Progression
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Length of Stay (statistics & numerical data)
  • Male
  • Middle Aged
  • Noninvasive Ventilation
  • Patient Readmission (statistics & numerical data)
  • Prospective Studies
  • Pulmonary Disease, Chronic Obstructive (complications)
  • Recurrence
  • Respiratory Insufficiency (therapy)
  • Spain
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: